This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse Effects

NCT07676669 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Bipolar 1 Depression

Interventions

DRUG: Lumateperone
DRUG: Cariprazine

Sponsor

Watim Medical & Dental College